BACKGROUND: Early detection and treatment of acute rejection in cardiac transplant recipients significantly improves long-term survival. Endomyocardial biopsy is used routinely for diagnosing allograft rejection; however, in young children, this procedure carries some risk. We evaluated serum vascular endothelial growth factor (VEGF) as a potential surveillance marker of acute cellular rejection. METHODS: Blood samples (n=62) were analyzed from 23 patients and compared with controls (n=18) using an ELISA for VEGF. Results were correlated with endomyocardial biopsy rejection grades. RESULTS: Mean baseline VEGF levels of the transplant population were consistently higher than controls. Serum VEGF levels were significantly higher during acute cellular rejection when compared with the non-rejecting transplant group (700.7+/-154 pg/ml vs. 190.5+/-29 pg/ml). VEGF decreased two- to eightfold after immunosuppressive therapy in 9 of 11 rejection episodes. CONCLUSIONS: These data suggest that VEGF may play a role in the pathogenesis of acute allograft rejection and it may serve as a reliable serologic surveillance marker.
BACKGROUND: Early detection and treatment of acute rejection in cardiac transplant recipients significantly improves long-term survival. Endomyocardial biopsy is used routinely for diagnosing allograft rejection; however, in young children, this procedure carries some risk. We evaluated serum vascular endothelial growth factor (VEGF) as a potential surveillance marker of acute cellular rejection. METHODS: Blood samples (n=62) were analyzed from 23 patients and compared with controls (n=18) using an ELISA for VEGF. Results were correlated with endomyocardial biopsy rejection grades. RESULTS: Mean baseline VEGF levels of the transplant population were consistently higher than controls. Serum VEGF levels were significantly higher during acute cellular rejection when compared with the non-rejecting transplant group (700.7+/-154 pg/ml vs. 190.5+/-29 pg/ml). VEGF decreased two- to eightfold after immunosuppressive therapy in 9 of 11 rejection episodes. CONCLUSIONS: These data suggest that VEGF may play a role in the pathogenesis of acute allograft rejection and it may serve as a reliable serologic surveillance marker.
Authors: Kevin P Daly; Maria Stack; Michele F Eisenga; John F Keane; David Zurakowski; Elizabeth D Blume; David M Briscoe Journal: J Heart Lung Transplant Date: 2016-10-03 Impact factor: 10.247
Authors: Mikio Okazaki; Andrew E Gelman; Jeremy R Tietjens; Aida Ibricevic; Christopher G Kornfeld; Howard J Huang; Steven B Richardson; Jiaming Lai; Joel R Garbow; G Alexander Patterson; Alexander S Krupnick; Steven L Brody; Daniel Kreisel Journal: Am J Respir Cell Mol Biol Date: 2007-08-23 Impact factor: 6.914
Authors: Rong Chen; Tara K Sigdel; Li Li; Neeraja Kambham; Joel T Dudley; Szu-Chuan Hsieh; R Bryan Klassen; Amery Chen; Tuyen Caohuu; Alexander A Morgan; Hannah A Valantine; Kiran K Khush; Minnie M Sarwal; Atul J Butte Journal: PLoS Comput Biol Date: 2010-09-23 Impact factor: 4.475
Authors: Kevin P Daly; Michael E Seifert; Anil Chandraker; David Zurakowski; Anju Nohria; Michael M Givertz; S Ananth Karumanchi; David M Briscoe Journal: J Heart Lung Transplant Date: 2013-01 Impact factor: 10.247
Authors: Sarah Bruneau; Craig Bryan Woda; Kevin Patrick Daly; Leonard Boneschansker; Namrata Gargee Jain; Nora Kochupurakkal; Alan Gabriel Contreras; Tatsuichiro Seto; David Michael Briscoe Journal: Front Immunol Date: 2012-04-02 Impact factor: 7.561
Authors: Natalia Kamieńska; Michał Zakliczyński; Alicja Kasperska-Zając; Marta Szewczyk; Dominika Trybunia-Orzeszek; Jerzy Nożyński; Marta Pijet; Tomasz Hrapkowicz; Marian Zembala Journal: Kardiochir Torakochirurgia Pol Date: 2014-06-29